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consequent release of Ca 2+ from the sarcoplasmic reticulum (SR) via RyR2 initiates myocyte contraction. Mutations in RYR2 that cause CPVT promote uncontrolled calcium leak from the SR, which may persist after depolarization, and can trigger lethal arrhythmias. 6 In autosomal-dominant CPVT, the RyR2 homotetrameric channel is composed of wild-type (WT) and mutant subunits which can combine in varying stoichiometries (4:0, 3:1, 2:2, 1:3, 0:4). Because RyR2 channels containing at least 1 mutant monomer can promote calcium leak, we reasoned that removing even a fraction of these mutant subunits could increase the proportion of fully functional WT channels in the R176Q/+ mice.
The CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 system uses an RNA-guided nuclease (Cas9) to make targeted double-stranded breaks in DNA. 7 These double-stranded breaks are most often repaired by the nonhomologous end-joining pathway in quiescent cell types, resulting in insertion and deletion mutations (indels). Because most indels are frameshifting, CRISPR/Cas9 editing can efficiently knock out alleles through the introduction of premature stop codons, splicing abnormalities, and nonsense-mediated decay of edited transcripts. 8 Because CPVT is often caused by gainof-function missense mutations in RYR2, we reasoned that this autosomal-dominant disease may serve as an excellent candidate for allele-specific disruption with CRISPR/Cas9. Reduced RyR2 levels were found to be well tolerated in RyR2 heterozygous mutant mice with CPVT, suggesting that a reduction in (mutant) RyR2 levels per se would not be expected to be harmful. 9 We designed guide RNAs (gRNA) to specifically target the disease-causing R176Q allele for disruption. The heterozygous R176Q/+ mice were previously shown to develop bidirectional or polymorphic ventricular tachycardia (VT) in response to adrenergic stress. 10 Adeno-associated viral (AAV) vectors were used to deliver the CRISPR/Cas9 machinery to cardiomyocytes in vivo to determine whether allele-specific disruption of Ryr2 expression could correct CPVT in live animals. Here, we show that AAV-CRISPR is both efficient and specific in the heart and that disruption of the R176Q mutant allele can prevent arrhythmogenesis in a CPVT mouse model.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request
Animal Studies
All studies were performed according to protocols approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine conforming to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (Publication no. 85-23, revised 1996). 11 We used R176Q/+ knock-in mice on a C57Bl6/J background that are maintained as an in-house breeding colony and genotyped as described. 10, 12 Similar numbers of male and female mice were used, and randomization to treatment groups took place at postnatal day 10. Inclusion criteria were successfully genotyped heterozygous R176Q/+ mice and WT littermates, 10 days of age; exclusion criteria were runt mice with a body weight <2 SD below the litter average. All analyses were performed in a blinded manner.
AAV Serotype 9 Production and Delivery
The AAV-CRISPR vector, 1255_pAAV-U6-SA-BbsI-MluI-gRNA-CB-SACas9-HA-OLLAS-spA was generated by the Lagor laboratory (Addgene plasmid 109320) based on the SaCas9 (Staphylococcus aureus Cas9) transgene from px602, Addgene plasmid 61593 (gift of Dr Feng Zhang). 13 Cloning details and AVV serotype 9 (AAV9) production procedures are provided in the Online Data Supplement. For systemic delivery of virus, mice on postnatal day 10 were subcutaneously injected with AAV9. Doses ranged from 5e11 to 1e12 genome copies/ mouse, delivered in a 50 µL volume of Ringer's lactate solution. Mice were randomly allocated to receive the different AAV9 treatments.
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Novelty and Significance
What Is Known?
• Catecholaminergic polymorphic ventricular tachycardia is an inherited disease of cardiac rhythm.
• More than 60% of catecholaminergic polymorphic ventricular tachycardia cases are caused by autosomal-dominant missense mutations in ryanodine receptor type 2 (RYR2).
• The CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 system can be used to edit the genome of living cells.
What New Information Does This Article Contribute?
• A single injection of adeno-associated virus was used to deliver CRISPR/Cas9 genome editing machinery to a mouse model of catecholaminergic polymorphic ventricular tachycardia.
• In vivo genome editing resulted in specific disruption of the diseasecausing Ryr2 allele, while sparing the normal copy of the gene.
• Gene editing reduced total RyR2 mRNA and protein levels and restored normal calcium handling.
• In vivo gene editing protected the R176Q/+ mice from pacing-induced cardiac arrhythmias.
The findings demonstrate that adeno-associated virus-CRISPR vectors can be used to treat a lethal inherited arrhythmia syndrome, through targeted removal of a pathogenic allele in vivo. Gene editing was specific for Ryr2 and reduced the amount of mutant but not the normal RyR2 allele. These studies highlight the promise of somatic genome editing for the treatment of catecholaminergic polymorphic ventricular tachycardia and other lethal autosomal-dominant diseases of the heart.
Programmed Intracardiac Stimulation
In vivo electrophysiology studies were performed at 5 to 6 weeks postinjection in similar numbers of male and female R176Q/+ mice and WT littermates, 14 see Methods in the Online Data Supplement. The experimenter was blinded to the genotype and type of AAV9 treatment.
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from ventricular tissues by TRIzol (Life technologies, 15596) and Direct-zol (ZYMO Research, R2072), and was reverse transcribed by iScript (Bio-Rad, 1708841). The iTaq Universal SYBR Green Supermix was used for the quantitative polymerase chain reaction (PCR) analysis of diluted cDNA in 1:10. Primers targeting upstream (exon 3-6) and downstream (exon 11-13) of the gRNA target site in Ryr2 are listed in Online Table I . The ΔΔCT method was used to calculate relative quantities normalized to Gapdh as the housekeeping gene.
Western Blot Analysis
Heart tissue was snap-frozen in liquid nitrogen. Western blotting was performed as described. To identify potential off-target sites in the mouse genome (mm9 and mm10), we applied COSMID (CRISPR Off-Target Sites With Mismatches, Insertions, and Deletions; https://crispr.bme.gatech.edu/) to find any off-target sites with 3 mismatches without insertion or deletion and 2 base mismatches with an insertion or deletion. 16 Genomic DNA was extracted from cardiac tissue by DNeasy kit (Qiagen, 69504) and was amplified by locus-specific primers (Online Table  I ) targeting on-or off-target sites using AccuPrime (Thermo Fisher, 12346086). All amplicons were then purified using the PCR Clean-up system (Promega, A9282). P5 and P7 adapter sequences and indexes for each sample identification were added by PCR; all barcoded amplicons in an equal molar ratio were pooled together and processed on the Illumina MiSeq platform by 2×250 paired-end sequencing. Nextgeneration sequencing data are available on the National Center for Biotechnology Information/ US National Library of Medicine website using the link: https://www.ncbi.nlm.nih.gov/sra/SRP155568.
Cellular Ca 2+ Imaging
Isolated ventricular myocytes were loaded with 2 µM Fluo-4-AM (Invitrogen, Carlsbad, CA) in normal Tyrode buffer solution (pH, 7.4±0.05) containing 1.8 mmol/L Ca 2+ and prepared for Ca 2+ sparks imaging, as described. 17 In brief, Ca 2+ sparks were recorded using linescan mode with 1024 pixels per line at 500 Hz on an LSM880 confocal microscope (Carl Zeiss, Thornwood, NY). One-Hz steady-state Ca 2+ transient pacing of myocytes was induced followed by a 20-s pause during which sparks were recorded. Ca 2+ spark frequency (CaSpF) was assessed with ImageJ software using SparkMaster plugin. Ca 
Statistical Analysis
Results are expressed as mean±SEM. For clustered data in which continuous variables were observed, generalized estimating equation was used via SPSS version 24 (IBM) or Prism using an unpaired Student t test or ANOVA, after performing the D'Agostino-Pearson normality test for normal distribution of the data. Categorical variables were evaluated with Fisher exact test. For multiple group comparison, 1-way ANOVA followed by Tukey post-test was used. P<0.05 was considered statistically significant.
Results
Design of an AAV-CRISPR Vector for Disruption of a Pathogenic Ryr2 Allele
To determine whether the mutant R176Q allele in heterozygous R176Q/+ mice with CPVT could be disrupted using gene editing, we used the CRISPR/Cas9 system from S. aureus, which is small enough to be packaged into AAV vectors together with the gRNA. A gRNA for SaCas9 was designed to target the mutant allele exclusively by binding to a silent restriction site present only in the knock-in allele, ≈15 bp from the mutation site ( Figure 1A ). The gRNA was cloned into an AAV9 vector driven by the U6 promoter with a downstream SaCas9 sequence driven by the ubiquitous chicken β-actin promoter ( Figure 1B) . A similar construct containing an empty gRNA cloning sites (BbsI) was used as the nontargeting control.
AAV9-Mediated Gene Editing Makes R176Q/+ Mice Resistant to Arrhythmia Induction
A single-dose systemic in vivo delivery of CRISPR/Cas9 was achieved by injecting 0.5 -1e12 genome copies of AAV9 subcutaneously into R176Q/+ mice at postnatal day 10. To test for functional correction of CPVT, we tested for susceptibility of these mice to VT after programmed electric stimulation at 5 to 6 weeks after AAV9 administration ( Figure 2A ). To mimic the adrenergic stimulation, mice were injected with isoproterenol (0.5 mg/kg, IP) and caffeine (120 mg/kg, IP). None of the WT mice treated with BbsI-SaCas9 (n=7) or gRNA-SaCas9 (n=6) exhibited sustained VT after programmed electric stimulation. As expected, we found that 71% of the R176Q/+ mice treated with the BbsI-SaCas9 negative control virus (n=7) developed sustained VT, including both polymorphic and bidirectional VT after programmed electric stimulation (P<0.05 versus WT). Remarkably, none of the R176Q/+ mice treated with gRNA-SaCas9 developed pacing-induced VT (0%, n=6; P<0.05; Figure 2B ). These findings indicate that allele-specific disruption of the R176Q/+ allele using AAV-mediated gene editing offers significant protection from VT. To determine whether gene editing altered cardiac contractility, echocardiography was performed on R176Q/+ mice treated with gRNA-SaCas9 or BbsI-SaCas9. There was no significant difference in ejection fraction or end-diastolic left ventricular diameter comparing both groups (Online Figure I) .
Evidence for Removal of the Mutant RyR2 Subunit in Mice Treated With AAV-CRISPR
To determine the mechanism underlying the therapeutic effects of CRISPR/Cas9 gene editing in our mouse model, we designed quantitative PCR primers targeting sequences upstream and downstream of Ryr2 exon 8, which contains the R176Q mutation ( Figure 3A) . Quantitative PCR was performed to measure the level of total Ryr2 mRNA in ventricular samples. R176Q/+ heterozygous mice treated with the gRNA-SaCas9 vector showed a roughly 30% decrease of total Ryr2 mRNA, compared with R176Q/+ mice receiving the nontargeting control virus (P<0.05; Figure 3B ). Similar results were obtained with quantitative PCR primers targeting sequences upstream and downstream of exon 8 ( Figure 3B ). In contrast, there was no change in Ryr2 mRNA levels in WT mice treated with the gRNA-SaCas9 vector compared with the control, suggesting a high degree of specificity of gene editing for the mutant allele.
Next, we examined possible splicing of exon 8 using reverse transcription PCR. Interestingly, we detected exon 8-deleted mRNA in cardiac tissue from R176Q/+ mice that September 28, 2018 received the gRNA-SaCas9 CRISPR vector (Online Figure  IIA) . The 113 base-pair deletion associated with splicingmediated removal of exon 8 causes a frameshift mutation predicted to cause a downstream stop codon in exon 9 after the translation of 29 aberrant amino acids. Amplicon sequencing of the lower molecular weight band confirmed splicing-mediated removal of exon 8 because the sequences of exon 7 and exon 9 were found to be contiguous (Online Figure IIB) .
We used a RyR2 antibody with an epitope downstream of the editing site (amino acid 2367) to only detect the fulllength RyR2 protein by western blotting ( Figure 3C ). In agreement with the mRNA data, the level of total RyR2 protein in R176Q/+ mice receiving the gRNA-SaCas9 vector was decreased by ≈25% compared with mice injected with control virus (P<0.05; Figure 3D ). Likewise, total RyR2 protein levels were not reduced in WT mice treated with the gRNA-SaCas9 vector, further supporting the specificity of our CRISPR editing strategy. Finally, we determined whether gene editing affected the levels of JPH2 (junctophilin-2), a key structural protein located near RyR2 within Ca 2+ release units in cardiomyocytes. Western blotting revealed that JPH2 protein levels were not affected ( Figure 3E ), indicating that RyR2 knockdown was a specific result of CRISPR editing rather than any disturbance of junctional membrane complexes.
High Allele-Specificity of the CRISPR/Cas9 System Targeting RyR2 Exon 8
To test the efficiency and specificity of our CRISPR editing approach, next-generation sequencing was performed using heart tissue obtained 5 to 6 weeks after AAV9 injection. Because of the high specificity of SaCas9 which has a complex protospacer adjacent motif (NNGRRT), only one potential off-target site was predicted by COSMID in the mouse genome. 16 Both the on-target site ( Figure 4A ) and off-target site were amplified and barcoded by PCR. There was no evidence of editing in WT mice receiving the gRNA-SaCas9 vector because the background indel frequency was low (0.10±0.01%) similar to WT mice receiving BbsI-SaCas9 control vector (0.10±0.00%; P=NS; Figure 4B ). Similarly, there was no nonspecific editing of the WT allele in heterozygous R176Q/+ mice receiving BbsI-SaCas9 (0.11±0.01%) or gRNA-SaCas9 vector (0.19±0.02%; P=NS), respectively. By contrast, there was a significantly higher indel frequency at the on-target site on the R176Q/+ allele in mice receiving gRNA-SaCas9 (11.3±1.39%) compared with BbsI-Cas9 (0.12±0.01%; P<0.01). Importantly, the indel frequency at the off-target site was much lower and not significantly increased in WT or R176Q/+ mice receiving gRNA-SaCas9 (Online Figure  III) . Finally, we analyzed the top 10 indels taking an average of 4 heart samples from R176Q/+ mice treated with gRNA-SaCas9 ( Figure 4C ). The majority of indel mutations were 1 to 2 base pairs in size, centered around position -3 relative to the protospacer adjacent motif. Such indels cause frameshifts that ultimately result in premature stop codons.
As shown in our recent report on Streptococcus pyogenes Cas9 (SpCas9) gene editing, 18 we also observed small insertion events containing sequences from the AAV inverted terminal repeats. Representative examples of AAV-based inverted terminal repeat (ITR) insertions are shown in Online Figure IV . In addition to small ITR insertions, PCR using primers specific to the AAV-CRISPR vector revealed evidence of whole vector genome insertions at the cut site, which occurred in both forward and reverse orientations (Online Figures V and  VI) . Thus far, these results indicate that our AAV-CRISPR vector can disrupt Ryr2 with high efficiency and specificity, introducing a spectrum of different mutations, which in aggregate reduce the protein levels of the mutant RyR2 subunit.
Impact of CRISPR/Cas9 Gene Editing on mRNA Transcripts
To gain a better understanding of the impact of gene editing on the relative amounts of WT and R176Q mutant mRNA transcripts, we performed deep sequencing of cDNA that was reverse transcribed from the same tissue samples. One of the primers was designed to bind within exon 8 to avoid capturing the exon 8-deleted transcript ( Figure 5A ). The relative proportions of mRNA transcribed from the WT or mutant allele of R176Q/+ mice were significantly altered in gRNASaCas9 treated R176Q/+ mice compared with those receiving BbsI-SaCas9 control vector (Online Figure VII) . There were significantly fewer cDNA reads containing the mutation (19.5%±1.1%) compared with WT reads (80.5%±1.1%; P<0.001), suggesting that the CRISPR-edited transcripts may exert differential effects on mRNA splicing and stability.
The background indel frequency in the cDNA samples was also low in WT mice receiving BbsI-SaCas9 (0.12±0.01%) or gRNA-SaCas9 (0.14±0.01%; P=NS) and R176Q/+ mice receiving BbsI-SaCas9 (0.13±0.01% of WT alleles; 0.11±0.01% of mutant alleles; P=NS; Figure 5B ). In contrast, there was a high indel frequency in the mutant allele of gRNA-SaCas9 treated R176Q/+ mice (21.1±1.51%), which is significantly higher than in the WT allele (0.23±0.01%; P<0.001). These results provide clear evidence for allele-specificity of gene editing in the R176Q/+ mice. Moreover, the higher indel frequency in mRNA (21%) compared with the genomic DNA (11%) is consistent with the assumption that ≈50% of the nuclei in cardiac tissue samples are derived from cardiomyocytes, which are the most abundant cell type in the heart expressing RyR2. Finally, we analyzed the top 10 indels in the amplified mRNA taking an average of 4 heart samples from R176Q/+ mice treated with gRNA-SaCas9. We found that the most common of these were generally consistent with the edits observed at the genomic level ( Figure 5C ).
AAV9-Mediated Normalized Intracellular Ca2+ Handling in R176Q/+ Mice
To determine the effects of AAV9-mediated gene editing on intracellular Ca 2+ handling, gRNA-SaCas9 (or BbsI-SaCas9 as control) and mCherry reporter vectors were coinjected in R176Q/+ mice. The reporter vector contains a STOP cassette flanked by 2 copies of the gRNA target sequence, which can be excised in the presence of gRNA and SaCas9. Fluorescent mCherry expression can be used to identify cardiomyocytes transduced with both AAV9 vectors that experience gene editing activity ( Figure 6A ). Confocal microscopy of ventricular myocytes isolated from R176Q/+ mice 5 to 6 weeks after treatment with gRNA-SaCas9 and reporter AAV9 revealed that 47% of the cells were positive for mCherry ( Figure 6B and C). In contrast, none of the myocytes were mCherry-positive in R176Q/+ mice that received the control BbsI-SaCas9 vector together with reporter ( Figure 6B and C) .
Next, myocytes were loaded with Ca 2+ fluorophore Fluo-4-AM and RyR2 activity was assessed by measuring the CaSpF after a 1-Hz conditioning train. Consistent with prior studies, 19 the CaSpF was significantly higher in myocytes from R176Q/+ mice (treated with BbsI-SaCas9; 2.3±0.5 a.u.) compared with those from WT mice (1.1±0.2 a.u.; P<0.001; Figure 6D ). The CaSpF was significantly lower in mCherry-positive myocytes from R176Q/+ mice+gRNA-SaCas9 (1.4±0.2 a.u.) in which gene editing occurred compared with mCherry-negative myocytes from the same animals (3.0±0.8 a.u.; P<0.01; Figure 6D ). These differences in CaSpF were not a consequence of alterations in SR Ca 2+ loading ( Figure 6E ). Finally, we measured the amplitude of SR Ca 2+ transients during 1-Hz field stimulation and did not observe significant differences among the groups. These data demonstrate that gene editing, as confirmed by the mCherry signal, led to normalization of SR Ca 2+ release in myocytes from R176Q/+ mice. 
Discussion
In this study, we applied somatic genome editing with CRISPR/Cas9 to correct a potentially lethal monogenic disorder of the heart. We demonstrated that a single AAV9 vector encoding both SaCas9 and gRNA caused efficient editing of cardiomyocytes in vivo. By specifically targeting the diseasecausing allele in a model of autosomal-dominant CPVT, our approach reduced levels of the mutant RyR2 subunit and restored normal cardiac function. In addition, we performed confocal imaging to test if the AAV9-mediated gRNA-SaCas9 gene editing therapy normalized intracellular Ca 2+ handling in R176Q/+ mice. The increased frequency of Ca 2+ sparks seen in untreated R176Q/+ mice was reduced to levels seen in WT mice with gRNA-SaCas9 treatment. In addition, the systolic Ca 2+ transients were not affected, demonstrating that the in vivo gene editing approach is effective and safe and that a mild reduction in overall RyR2 protein levels does not affect cardiac contractility. Thus, our editing strategy was efficient and specific and prevented catecholamine-induced VT in a relevant mouse model of this human disease.
Recent articles have shown that AAV9 vectors can deliver CRISPR/Cas9 to the heart to somatically knock out genes. 20, 21 These studies have relied on the commonly used SpCas9 system, which presents delivery challenges with AAV because of its size. In these cases, the gRNA must either be delivered via a separate vector or be introduced into SpCas9 transgenic mice. Because the SaCas9 is ≈1 kb smaller than SpCas9, it can fit with together with the gRNA into a single AAV vector. 13 AAV-SaCas9 has been used successfully for gene editing in liver, 13, 22, 23 skeletal muscle, 24, 25 and recently in heart for excision of exon 23 from the mdx model of Duchenne muscular dystrophy. 26 In related work, Xie et al 27 generated transgenic and knock-in mice to model the H530R mutation in the PRKAG gene, which causes nonsarcomeric familial hypertrophic cardiomyopathy associated with WolffParkinson-White in humans. These authors used a dual vector AAV9-based system to deliver SpCas9 along with a gRNA to disrupt the mutant allele. Indel rates were in the range of ≈2.6 to 6.5% in mice injected as neonates. In their study, disruption was specific for the disease-causing PRKAG allele and fully restored heart morphology and function. In our study, we were able to achieve much higher indel rates for the R176Q mutant allele (11.3% of genomic, 21.1% of mRNA) in R176Q/+ mice that received the gRNA-SaCas9 vector. To our knowledge, our study is the first example of such efficient somatic gene editing in cardiac myocytes, which effectively cured a lethal autosomal-dominant disease of the heart. We examined allele-specific editing in detail at the DNA, mRNA, and protein levels. Our gRNA was specific to the R176Q mutant Ryr2 allele, with no evidence for mutagenesis Figure 5 . Validation of the efficiency and specificity of gene editing of the ryanodine receptor type 2 (RyR2) mutation allele in cDNA using deep sequencing. A, Sequencing amplicon covering exon 6 through 8. Red line marks the mutation in R176Q allele. Target sequence is marked with the blue bar, and protospacer adjacent motif (PAM) sequence is marked using the orange bar. B, Frequency of insertion or deletion mutations (indels) in cDNA at the ontarget RyR2 site in wild-type (WT) and R176Q/+ mice (n=4). C, Most common indels in cDNA observed at the target site. Insertions are marked with red and deletions are represented by dash line. Target sequence is highlighted in blue and PAM is marked as above. ***P<0.001. AAV indicates adeno-associated virus; and gRNA, guide RNA.
of the WT Ryr2. Allele-specificity is critical in the case of CPVT arising from RYR2 mutations, as the calcium release channel is mandatory for proper excitation-contraction coupling in the heart. It is currently unknown whether a 20% to 25% reduction in total RyR2 in humans would create new pathology, and this would need to be addressed through human genetics of rare variants and studies in relevant cell systems. The indels at the cut site were primarily frameshifting insertions or deletions that are expected to promote nonsense-mediated decay, consistent with the reduced mRNA levels.
In this study, we found fragments of the ITRs, as well as whole AAV-CRISPR vector genomes inserted at the cut site in Ryr2. Whole vector genome insertions were an unexpected consequence which occurred only in the R176Q/+ mutant mice that received the AAV vector expressing the gRNA. It is noteworthy that these were not found in WT mice receiving the AAV-CRISPR vector, further emphasizing the specificity of the gRNA for the mutant allele. Although it is not technically possible to quantify these insertions relative to the shorter indels, they may represent a substantial fraction of the mutant alleles. This may help explain why apparently modest rates of editing detected by next-generation sequencing could cause such a striking correction of CPVT. All of these large insertions would prevent expression of the mutant RyR2 protein subunit. This does, however, present an additional safety concern of on-target insertional mutagenesis that merits further investigation.
In addition to a reduction in the total mRNA level for Ryr2, we also observed skipping of exon 8. Consistent with a previous report, 28 this accounted for a relatively small fraction of all the gRNA-modified sequences. In addition to allelespecificity, we found no evidence of off-target mutagenesis at predicted sites. This is logical, given the restrictive protospacer adjacent motif of SaCas9 (NNGRRT), which minimizes potential off-target sites elsewhere in the genome but also greatly limits target site selection. The development of refined genome editing tools, such as KKH SaCas9, will be invaluable in expanding the targeting capability of this system. 29 A limitation of our study is that the gRNA does not bind to the exact mutation site but an artificial adjacent sequence in the R176Q model. Nonetheless, we provide compelling evidence that AAV-SaCas9 vectors can efficiently edit Ryr2 in an allele-specific manner, rescuing CPVT pathology. Moreover, we provide a platform for targeting other previous reported mutations also located in exon 8, including P164S, R169Q, V186M, and E189D. 30 Recently, Bongianino et al 9 performed allele-specific silencing of mutant Ryr2 through AAV9 expressed shRNA (small hairpin RNA) in another mouse model of CPVT. In this case, the R4496C mutant RyR2 subunit was selectively silenced at the mRNA level, resulting in a net 15% reduction in total RyR2 protein levels. This AAV9-shRNA vector corrected mitochondrial and junctional SR/T-tubule abnormalities and reduced the incidence of adrenergicallystimulated VT in the mice. 9 This study and ours support the concept of removing disease-causing Ryr2 alleles as a viable therapeutic approach to treat CPVT. However, RNA interference and antisense approaches still have significant specificity and delivery challenges for targeting human cardiomyocytes. In the case of CPVT, repeated and chronic dosing would be needed for life. In contrast, a single-dosed AAV-CRISPR genome editing approach is particularly attractive and would be potentially curative if demonstrated to be safe and specific enough for clinical trials.
There is currently no consensus on what large animal preclinical models are best suited to address issues of CRISPR/ Cas9 efficiency, specificity, efficacy, and safety. In addition, off-target mutagenesis is likely to be dependent on the patient-specific gRNA and will vary based on the potential sites present in the rest of their unique genomes. Recent studies have shown promising results using AAV9-based vectors in a clinical study involving patients with spinal muscular atrophy type 1. 31 A single dose of intravenous AAV9 coding for the missing survival motor neuron 1 results in longer survival and superior motor function compared with a historic cohort of patients without such treatment. AAV9 has also been used extensively for gene delivery to heart and skeletal muscle in mice, include recent genome editing studies for Duchenne muscular dystrophy. 24, 25 Because RyR2 is also expressed in other cell types, such as smooth muscle cells and neurons, AAV9-based approaches might be developed to correct RyR2 mutations in those cell types. This may even be important for the treatment of CPVT because we have demonstrated that mutant RyR2 can contribute to neuronal deficits that contribute to arrhythmia development in CPVT mice. 32 The editing of neuronal RyR2 mutants would be therapeutic rather than harmful in this context. However, it has been demonstrated that only high doses of AAV9 can cross the blood-brain barrier and may transduce neurons. 33 Therefore, it is possible but unlikely (given the AAV9 dose used in this study) that editing of neurons contributed to the prevention of arrhythmias. Nevertheless, in future studies, neuronal gene editing might be exploited for the treatment of cardiac arrhythmias in addition to direct cardiomyocyte targeting. In summary, our findings demonstrate that AAV9-mediated gene editing may be a promising treatment modality of inherited monogenic diseases, such as CPVT.
